PLUS1
26.9258
0.8358 (3.2%)
0.8358 (3.2%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Arcutis Biotherapeutics Inc | ARQT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.8358 | 3.2% | 26.9258 | 12:33:59 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 26.75 | 25.94 | 27.26 | 26.09 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 26.91 | 26.96 | 0.05 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,302 | 96,798 | $ 26.47 | $ 2,562,254 | 192,639 | 17.10 - 40.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:34:37 | 13 | $ 26.924 | USD |
Arcutis Biotherapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.17B | 43.63M | 23.45M | $ - | $ - | -1.20 | -9.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 560.99k | 4.50% |
Arcutis Biotherapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/23/2020 | 07:30 | GlobeNewswire Inc. | Arcutis Announces Positive Topline Data from Phase 2b Study.. |
| 11/13/2020 | 11:57 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/11/2020 | 16:05 | GlobeNewswire Inc. | Arcutis Biotherapeutics to Present at the Stifel 2020.. |
| 11/05/2020 | 16:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/05/2020 | 16:05 | GlobeNewswire Inc. | Arcutis Announces Third Quarter 2020 Financial Results and.. |
| 11/04/2020 | 16:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/04/2020 | 16:34 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARQT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 24.16 | 27.26 | 23.61 | 25.44 | 153,818 | 2.77 | 11.45% |
| 1 Month | 17.98 | 27.26 | 17.51 | 21.28 | 167,733 | 8.95 | 49.75% |
| 3 Months | 24.21 | 31.43 | 17.51 | 23.62 | 243,418 | 2.72 | 11.22% |
| 6 Months | 34.33 | 39.8527 | 17.51 | 25.12 | 163,138 | -7.40 | -21.57% |
| 1 Year | 23.05 | 40.88 | 17.10 | 25.94 | 159,384 | 3.88 | 16.81% |
| 3 Years | 23.05 | 40.88 | 17.10 | 25.94 | 159,384 | 3.88 | 16.81% |
| 5 Years | 23.05 | 40.88 | 17.10 | 25.94 | 159,384 | 3.88 | 16.81% |
Arcutis Biotherapeutics Description
| Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The firm's lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. |
